Finerenone and NYHA Functional Class in Heart Failure
In this FINEARTS-HF analysis, finerenone reduced clinical outcomes and improved patient-reported health status in HF with mildly reduced or preserved ejection fraction irrespective of baseline NYHA functional class. (Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients with Heart Failure [FINEARTS-HF]; NCT04435626).
Authors
- Brian Lee Claggett (ORCID: https://orcid.org/0000-0002-4215-9218)
- Pardeep S. Jhund (ORCID: https://orcid.org/0000-0003-4306-5317)
- John W. Ostrominski (ORCID: https://orcid.org/0000-0002-2866-9414)
- James Lay‐Flurrie
- John J.V. McMurray (ORCID: https://orcid.org/0000-0002-6317-3975)
- Faiez M. Zannad (ORCID: https://orcid.org/0000-0001-7456-1570)
- Katja Rohwedder
- Bertram Pitt (ORCID: https://orcid.org/0000-0001-5880-275X)
- Michele Senni (ORCID: https://orcid.org/0000-0001-5502-7882)
- Muthiah Vaduganathan (ORCID: https://orcid.org/0000-0003-0885-1953)
- Adriaan A. Voors (ORCID: https://orcid.org/0000-0002-5417-4415)
- Akshay S. Desai (ORCID: https://orcid.org/0000-0002-1443-0701)
- Sanjiv J. Shah (ORCID: https://orcid.org/0000-0002-5655-8201)
- Maria Borentian
- Scott D Solomon
- Marco Lavagnino
Institutions
- Northwestern University (US)
- Brigham and Women's Hospital (US)
- University Medical Center Groningen (NL)
- Harvard University (US)
- Inserm (FR)
- National University of Singapore (SG)
- University of Michigan (US)
- British Heart Foundation (GB)
- Ospedale Papa Giovanni XXIII (IT)
- National University Heart Centre Singapore (SG)
- National Heart Centre Singapore (SG)
- University of Milano-Bicocca (IT)
- Bayer (Germany) (DE)
- University of Glasgow (GB)
- Université de Lorraine (FR)
Publication Details
- Journal
- JACC Heart Failure
- Published
- 2025-04-03
- DOI
- https://doi.org/10.1016/j.jchf.2025.03.007
- Citations
- 3
- Primary Topic
- Hormonal Regulation and Hypertension
- Type
- article
- Field-Weighted Citation Impact
- 3.88
Funders
- Bayer